Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Pluripotent stem cell-derived natural killer cells for cancer therapy.

Knorr DA, Kaufman DS.

Transl Res. 2010 Sep;156(3):147-54. doi: 10.1016/j.trsl.2010.07.008. Epub 2010 Aug 1. Review.

2.

Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy.

Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, Lee DA, Kaufman DS.

Stem Cells Transl Med. 2013 Apr;2(4):274-83. doi: 10.5966/sctm.2012-0084. Epub 2013 Mar 20.

3.

Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.

Wang D, Quan Y, Yan Q, Morales JE, Wetsel RA.

Stem Cells Transl Med. 2015 Oct;4(10):1234-45. doi: 10.5966/sctm.2015-0049. Epub 2015 Aug 18.

4.

Hematopoietic and nature killer cell development from human pluripotent stem cells.

Ni Z, Knorr DA, Kaufman DS.

Methods Mol Biol. 2013;1029:33-41. doi: 10.1007/978-1-62703-478-4_3.

PMID:
23756940
5.

Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells.

Kaufman DS.

Blood. 2009 Oct 22;114(17):3513-23. doi: 10.1182/blood-2009-03-191304. Epub 2009 Aug 3. Review.

6.

In vitro generation of immune cells from pluripotent stem cells.

Vandekerckhove B, Vanhee S, Van Coppernolle S, Snauwaert S, Velghe I, Taghon T, Leclercq G, Kerre T, Plum J.

Front Biosci (Landmark Ed). 2011 Jan 1;16:1488-504. Review.

PMID:
21196243
7.

Differences in lymphocyte developmental potential between human embryonic stem cell and umbilical cord blood-derived hematopoietic progenitor cells.

Martin CH, Woll PS, Ni Z, Zúñiga-Pflücker JC, Kaufman DS.

Blood. 2008 Oct 1;112(7):2730-7. doi: 10.1182/blood-2008-01-133801. Epub 2008 Jul 11.

8.

Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons.

Sundberg M, Bogetofte H, Lawson T, Jansson J, Smith G, Astradsson A, Moore M, Osborn T, Cooper O, Spealman R, Hallett P, Isacson O.

Stem Cells. 2013 Aug;31(8):1548-62. doi: 10.1002/stem.1415.

11.

Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy.

Knorr DA, Bock A, Brentjens RJ, Kaufman DS.

Stem Cells Dev. 2013 Jul 1;22(13):1861-9. doi: 10.1089/scd.2012.0608. Epub 2013 Mar 28.

12.

Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity.

Woll PS, Grzywacz B, Tian X, Marcus RK, Knorr DA, Verneris MR, Kaufman DS.

Blood. 2009 Jun 11;113(24):6094-101. doi: 10.1182/blood-2008-06-165225. Epub 2009 Apr 13.

13.

Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma.

Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA.

Biol Blood Marrow Transplant. 2001;7(10):532-42.

PMID:
11760085
14.

Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.

Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW.

Blood. 2004 Jul 1;104(1):170-7. Epub 2004 Mar 11.

15.

Invariant natural killer T cells in immune surveillance and tumor immunotherapy: perspectives and potentials.

Haeryfar SM.

Arch Iran Med. 2008 Mar;11(2):186-95. doi: 08112/AIM.0012. Review.

16.

Concise review: human pluripotent stem cells in the treatment of spinal cord injury.

Lukovic D, Moreno Manzano V, Stojkovic M, Bhattacharya SS, Erceg S.

Stem Cells. 2012 Sep;30(9):1787-92. doi: 10.1002/stem.1159. Review.

17.

GMP scale-up and banking of pluripotent stem cells for cellular therapy applications.

Ausubel LJ, Lopez PM, Couture LA.

Methods Mol Biol. 2011;767:147-59. doi: 10.1007/978-1-61779-201-4_11.

PMID:
21822873
18.

Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies.

Kolb HJ, Simoes B, Schmid C.

Curr Opin Oncol. 2004 Mar;16(2):167-73. Review.

PMID:
15075911
19.

Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer/natural killer cells in K562 NOD/SCID mice.

Li Y, Qu YH, Wu YF, Wang XP, Wei J, Huang WG, Zhou DH, Fang J, Huang K, Huang SL.

Ann Hematol. 2011 Aug;90(8):873-85. doi: 10.1007/s00277-011-1156-9. Epub 2011 Jan 15.

PMID:
21234566
20.

Perspectives and future directions of human pluripotent stem cell-based therapies: lessons from Geron's clinical trial for spinal cord injury.

Lukovic D, Stojkovic M, Moreno-Manzano V, Bhattacharya SS, Erceg S.

Stem Cells Dev. 2014 Jan 1;23(1):1-4. doi: 10.1089/scd.2013.0266. Epub 2013 Oct 4.

PMID:
23980630

Supplemental Content

Support Center